For healthcare professionals in the UK and ROI only
GPnotebook

This promotional website has been developed and funded by Boehringer Ingelheim.
The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.

Prescribing information for the United Kingdom and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Resources for you.

Discover educational resources designed specifically for HCPs to support your learning and development in key areas related to the management of T2D in adults.

Check out our latest on-demand content:

The evolving landscape: Type 2 diabetes management and diabetes-related mental health

Professor Richard Holt & Nicola Milne

What these resources explore:

  • The impact of T2D on mental wellbeing
  • Why awareness, education and integrated care matter in T2D and mental health care
  • Recognising when a person with T2D is struggling with their mental wellbeing
  • Case-based examples to explore strategies for managing people living with T2D and mental health conditions
Watch video summary

Video summary

09:27

Watch video

42:01

Webinar video

Download leaflet

HCP leaflet

Downloadable one-page leaflets

HCP leaflet

Complex comorbidities

Best practice for managing T2D in people living with complex comorbidities

Download a one-page leaflet that highlights a case-based approach to managing T2D in adults with complex comorbidities, reflecting on key considerations and learnings from case snapshots.

Download leaflet

HCP leaflet

Treatment non-adherence

Addressing treatment non-adherence when managing adults living with T2D

Access this one-page leaflet that explores the factors that affect treatment adherence, the potential consequences of non-adherence, and practical tips to help address non-adherence in adults living with T2D.

Download leaflet

HCP leaflet

Ramadan and fasting

Recommendations for managing adults living with T2D during Ramadan and periods of fasting

Find out more about the risks associated with fasting for people living with T2D, key considerations when making medication and insulin modifications, and how these recommendations apply to three fictional patient cases.

Download leaflet

Back to top

CKD: chronic kidney disease; CVD: cardiovascular disease; HCP: healthcare professional; T2D: type 2 diabetes.

Please review the Summary of Product Characteristics for Linagliptin for the full information on dosing, adverse events, contraindications, special warnings and precautions for use before prescribing. Available at: www.medicines.org.uk (UK) and https://www.medicines.ie (ROI).1

Reference

  1. Linagliptin Summary of Product Characteristics. Available at: https://www.medicines.org.uk (UK) and https://www.medicines.ie (ROI).

Prescribing information for the United Kingdom and the Republic of Ireland.

Linagliptin is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as1:

• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

This promotional website has been developed and funded by Boehringer Ingelheim.
Editorial support for this website has been provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), or by email: [email protected]

PC-GB-112302 | May 2026

This website is for healthcare professionals in the United Kingdom and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in the United Kingdom or the Republic of Ireland by clicking below.

I am
I am not

Linagliptin prescribing information: UK and ROI.

You are leaving https://resources.gpnotebook.com

Text

Text

Close

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel